GLAXOSMITHKLINE ORD GBP0.25
Symbol: GSK
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Overview
Core Data
Latest Dividend Information
| Ex-Dividend Date | 12 Nov 2020 |
| Pay Date | 14 Jan 2021 |
| Total Dividends - Year to Date | 80 |
| Dividend Yield (%) | 5.7414 |
Historical Data & Ratios
| Avg Volume Over 10 Days | 6.7225 |
| Market Cap (M) | 69041.5500 |
| Price/Earnings (PE) | 10.8664 |
| Earnings Per Share | 128.23 |
| Revenue Per Share | 6.7293 |
| Return on Equity % | 58.9280 |
1 Month Performance Chart
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy10 |
Buy1 |
Neutral11 |
Sell0 |
Strong Sell1 |
|---|---|---|---|---|---|
| Brokers | 10 | 1 | 11 | 0 | 1 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here |
0.35% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
N/A | N/A |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Charts
Company
Business Summary
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Financial Summary
BRIEF: For the nine months ended 30 September 2020,GlaxoSmithKline plc revenues increased 2% to £25.36B. Netincome increased 52% to £5.07B. Revenues reflect ConsumerHealthcare segment increase of 19% to £7.67B, US segmentincrease of 5% to £10.67B, Europe segment increase of lessthan 1% to £6.07B. Net income benefited from Unallocatedsegment loss decrease of 80% to £462M, Consumer Healthcaresegment income increase of 27% to £1.83B.
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
31/12/2019 |
31/12/2018 |
31/12/2017 |
31/12/2016 |
31/12/2015 |
31/12/2014 |
|---|---|---|---|---|---|---|
| Total Revenue | 33,754.00 | 30,821.00 | 30,186.00 | 27,889.00 | 23,923.00 | 23,006.00 |
| Gross profit | 23,586.00 | 21,249.00 | 20,869.00 | 18,991.00 | 15,881.00 | 15,968.00 |
| Operating Profit/Loss | 6,961.00 | 5,486.00 | 4,181.00 | 2,598.00 | 11,165.00 | 3,597.00 |
| Profit Before Tax | 6,221.00 | 4,800.00 | 3,525.00 | 1,939.00 | 10,526.00 | 2,968.00 |
| Profit After Tax | 5,268.00 | 3,921.00 | 3,247.00 | 1,062.00 | 8,372.00 | 2,831.00 |
| Equity Holders of Parent Company | 4,645.00 | 3,623.00 | 1,532.00 | 912.00 | 8,422.00 | 2,756.00 |
| Minority Interest | 6,329.00 | -1,111.00 | 2,920.00 | 3,689.00 | 3,814.00 | 598.00 |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
31/12/2019 |
31/12/2018 |
31/12/2017 |
31/12/2016 |
31/12/2015 |
31/12/2014 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 60,201.00 | 41,139.00 | 40,474.00 | 42,370.00 | 36,859.00 | 25,973.00 |
| Total Current Assets | 19,491.00 | 16,927.00 | 15,907.00 | 16,711.00 | 16,587.00 | 14,678.00 |
| Total Assets | 79,692.00 | 58,066.00 | 56,381.00 | 59,081.00 | 53,446.00 | 40,651.00 |
| Total Liabilities | 61,335.00 | 54,394.00 | 52,892.00 | 54,118.00 | 44,568.00 | 35,715.00 |
| Total Net Assets | 18,357.00 | 3,672.00 | 3,489.00 | 4,963.00 | 8,878.00 | 4,936.00 |
| Shareholders Funds | 11,405.00 | 4,360.00 | -68.00 | 1,124.00 | 5,114.00 | 4,263.00 |
| Minority Interests | 6,329.00 | -1,111.00 | 2,920.00 | 3,689.00 | 3,814.00 | 598.00 |
| Total Equity | 18,357.00 | 3,672.00 | 3,489.00 | 4,963.00 | 8,878.00 | 4,936.00 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy10 |
Buy1 |
Neutral11 |
Sell0 |
Strong Sell1 |
|---|---|---|---|---|---|
| Brokers | 10 | 1 | 11 | 0 | 1 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Forecasts
| Year | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue | £34,211.90mn | £35,326.70mn | £36,888.40mn |
| Pre-tax-Profit | £8,222.75mn | £8,438.59mn | £9,012.37mn |
| EPS | £1.16p | £1.15p | £1.23p |
| EPS Growth | -6.32% | -1.07% | 7.51% |
| P/E | 12.02 | 12.15 | 11.3 |
| PEG Ratio | -1.90 | -11.33 | 1.50 |
| Dividend | 80.00p | 80.00p | 79.70p |
| Yield | 5.68% | 5.68% | 5.66% |
Upgrades & Downgrades (Latest 10)
| Date | Broker | Recommendation | Price | Old Target | New Target | Change |
|---|---|---|---|---|---|---|
| 2nd Nov 2020 | Liberum Capital | Upgrade | 1325p | 1840p | 1730p | Buy |
| 29th Oct 2020 | Shore Capital | Reiteration | 1304p | 0p | 0p | Sell |
| 15th Oct 2020 | Shore Capital | Reiteration | 1376p | 0p | 0p | Sell |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown.
| Date | Time | Price | Volume | Type |
|---|---|---|---|---|
| 15 Jan 2021 | 14:28 | 1,405.8 | 151 | Buy |
| 15 Jan 2021 | 14:28 | 1,405.8 | 255 | Buy |
| 15 Jan 2021 | 14:28 | 1,405.8 | 27 | Buy |
| 15 Jan 2021 | 14:27 | 1,405.6 | 400 | Sell |
| 15 Jan 2021 | 14:27 | 1,405.8 | 3 | Buy |
| 15 Jan 2021 | 14:27 | 1,405.6 | 250 | Sell |
| 15 Jan 2021 | 14:27 | 1,405.6 | 76 | Sell |
| 15 Jan 2021 | 14:27 | 1,405.6 | 150 | Sell |
| 15 Jan 2021 | 14:27 | 1,405.6 | 10 | Sell |
| 15 Jan 2021 | 14:27 | 1,405.6 | 316 | Buy |
| 15 Jan 2021 | 14:27 | 1,405.6 | 315 | Buy |
| 15 Jan 2021 | 14:27 | 1,405.6 | 1,883 | Buy |
| 15 Jan 2021 | 14:27 | 1,406 | 172 | Sell |
| 15 Jan 2021 | 14:27 | 1,406.2 | 486 | Sell |
| 15 Jan 2021 | 14:27 | 1,406.2 | 239 | Sell |
| 15 Jan 2021 | 14:27 | 1,406.2 | 540 | Sell |
| 15 Jan 2021 | 14:27 | 1,406 | 459 | Sell |
| 15 Jan 2021 | 14:27 | 1,406 | 165 | Sell |
| 15 Jan 2021 | 14:27 | 1,406 | 42 | Sell |
| 15 Jan 2021 | 14:27 | 1,406.2056 | 402 | Buy |
Selected data supplied by Thomson Reuters © View restrictions.